PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R). PIPE-791 is being evaluated for the treatment of chronic pain associated with two ...

Contineum Therapeutics, Inc.’s CTNM share price has surged by 6.08%, which has investors questioning if this is right time to ...

PIPE-791, for treating idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. In December 2024, the company dosed the first subject cohort in the Phase Ib positron ...

A prospectus filed with the Securities and Exchange Commission (SEC) notes that Contineum has completed a phase 1 study of its lead in-house candidate PIPE-791 in healthy volunteers and hopes to ...

PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 ...

JonesResearch analyst Debanjana Chatterjee initiated coverage of Contineum (CTNM) with a Buy rating and $23 price target The company’s lead clinical-stage asset is PIPE-791, an LPA1 receptor ...

PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 ...

PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R). PIPE-791 is being evaluated for the treatment of chronic pain associated with two ...